Technology | January 28, 2014

Gore Receives FDA Approval for 25 cm Gore Viabahn Endoprosthesis

Longest stent-graft introduced in the United States

Gore Viabahn Endoprosthesis Heparin Bioactive Surface Stent Grafts Aneurism
January 28, 2014 — The U.S. Food and Drug Administration (FDA) approved W. L. Gore & Associates’ 25 cm Gore Viabahn Endoprosthesis with Heparin Bioactive Surface for the treatment of symptomatic peripheral arterial disease (PAD) lesions in the Superficial Femoral Artery (SFA). The 25 cm endoprosthesis is designed to cover long-segment lesions in the SFA, potentially reducing the need for multiple devices.
 
The FDA approval of the 25 cm device was supported by evidence from a multicenter European trial. Patients enrolled in the study had lesion lengths ranging from 20 to 40 cm, with a mean length of 26.5 cm. Of all patients enrolled, 92.9 percent had total occlusions of the SFA. One-year data demonstrated a freedom from target lesion revascularization of 78.2 percent. In addition, the Gore Viabahn device exhibited no fractures at 12 months.
 
The 25 cm study results supplement data from a physician-sponsored investigational device exemption (IDE) trial conducted previously. 
 
“We have been awaiting the approval of the 25 cm [Gore Viabahn device] since our study directly comparing the [Gore Viabahn] Stent-graft as an endoluminal bypass in the SFA to open femoral popliteal bypass of the SFA was completed,” said Dennis Gable, M.D., vascular surgeon at The Heart Hospital Baylor Plano, Plano, Texas. “Our results demonstrated no difference in primary patency or limb salvage out to four years when comparing the two treatment modalities—even with a mean stented length of 25.6 cm in the [Gore Viabahn device] arm. Our study results are supported by the similar outcomes of the European data and show that treatment of truly long lesions can now successfully be accomplished with only one stent device with excellent results.”
 
The stent-graft design of the Gore Viabahn Endoprosthesis with Heparin Bioactive Surface consists of a durable, reinforced, biocompatible, ePTFE liner attached to an external nitinol stent structure that acts as a barrier to in-stent restenosis. The device is available in configurations that are compatible with 0.035 in or 0.018/0.014 in wire platforms. The device also incorporates the Heparin Bioactive Surface, which utilizes a proprietary end-point covalent immobilization of heparin to the surface of the endoprosthesis. This proprietary surface technology is intended to provide a thromboresistant surface through sustained heparin bioactivity.
 
For more information: www.goremedical.com

Related Content

The researchers used high resolution cross-sectional imaging with CT or MRI to assess 225 men with abdominal aortic aneurysm. Follow-up lasted, on average, more than three years.  Slightly more than half of patients had an intraluminal thrombus. The aneurysms of those with intraluminal thrombus were larger at baseline and grew by a rate of 2 mm per year, twice as fast as the 1 mm per year growth rate in people without intraluminal thrombus.
News | Endovascular Aortic Repair | January 29, 2020
January 29, 2020 – The presence of a blood clot on the wall of the aorta in people with...
The Endospan Ltd. Nexus aortic arch stent graft is a CE mark–approved, off-the-shelf system for endovascular treatment of pathologies extending or involving the aortic arch.  #VIVA19 #VIVA2019

The Endospan Ltd. Nexus aortic arch stent graft is a CE mark–approved, off-the-shelf system for endovascular treatment of pathologies extending or involving the aortic arch. 

News | Endovascular Aortic Repair | November 11, 2019
November 7, 2019 — The Endospan Ltd.
Obese Patients Have More Post-Op Problems Following AAA Repair
News | Endovascular Aortic Repair | November 21, 2018
New research in the December edition of the Journal of Vascular Surgery suggests significant increase in morbidities in...
FDA Classifies Previous Endologix AFX Safety Notice as Class I Recall
News | Endovascular Aortic Repair | October 08, 2018
Endologix Inc. received notice that the U.S. Food and Drug Administration (FDA) has classified a voluntary recall...
The Gore TAG stent graft used in TEVAR aortic repair procedures for aneurysms.

The Gore TAG stent graft used for endovascular aortic aneurysm repair procedures.

Feature | Endovascular Aortic Repair | February 05, 2018 | Andrei Churyla, M.D., S. Chris Malaisrie, M.D.
Here are several considerations for physicians when choosing...
Endologix Receives IDE Approval for EVAS2 Confirmatory Clinical Study
News | Endovascular Aortic Repair | October 19, 2017
Endologix Inc. received Investigational Device Exemption (IDE) approval from the U.S. Food and Drug Administration (FDA...
New Paper Highlights Success of Advanced Treatments in Complex Aortic Aneurysm Repair
News | Endovascular Aortic Repair | May 23, 2017
Significant success has been achieved in treating complex proximal aneurysms using a combination of fenestrated and...
abdominal aortic aneurysm, AAA, gender differences, women vs. men, endovascular repair, Journal of Vascular Surgery study
News | Endovascular Aortic Repair | April 05, 2017
Following repair of abdominal aortic aneurysms (AAA), women appear to have more unfavorable outcomes than men in terms...
Beaumont Hospital, Michigan, endovascular aortic repair, EVAR, conscious sedation
News | Endovascular Aortic Repair | July 08, 2016
Kirk Schoenherr, 56, of Clinton Township, Mich., recently became just the second patient at Beaumont Hospital, Royal...